Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 822 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Determining Fluid Requirements March 26, 2021 Exosomes May Help Tumors Evade Immune System September 7, 2018 Evaluation of Primary and Secondary Prevention of Oral Cancer October 28, 2022 EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria October 2, 2020 Load more HOT NEWS Minimizing Time Between Diagnosis and End of Treatment Improves Breast Cancer... ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ) Four randomized prospective degree compared 90 days regarding neoadjuvant ADT observed... Idecabtagene Vicleucel Prolongs PFS and Improves Response Compared with Standard Regimens...
